← Back to Search

Narrative Medicine for Parental Coping in Child Intensive Care

N/A
Waitlist Available
Led By Daniel H Grossoehme, DMin, MS
Research Sponsored by Akron Children's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 3 days post intervention/baseline
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a narrative medicine intervention for caregivers of children in the PICU. The intervention includes reading, discussing, and writing about selected texts to help caregivers cope with stress. The goal is to see if this approach improves their mental well-being.

Who is the study for?
This trial is for legal guardians aged 18 or older who can read and write English, with a child under 18 years in the PICU on hospitalization day 5 or more. It's not for those whose partner is in a similar study, have joined this study before, if their child isn't officially under PICU service, or if they work in Akron Children's Hospital Palliative Care.
What is being tested?
The trial tests narrative medicine as a coping strategy for parents with children in intensive care. It involves reading literature followed by discussion and writing exercises guided by a coordinator. The impact of these sessions on the parents' ability to cope and make sense of their experience is measured through surveys.
What are the potential side effects?
There are no direct physical side effects from participating in narrative medicine interventions like this one. However, discussing sensitive topics may evoke emotional responses or discomfort.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 3 days post intervention/baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 3 days post intervention/baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Edmonton Symptom Assessment Scale (ESAS)
Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being (FACIT-Sp-12) Meaning subscale
Secondary study objectives
Duke University Religion Index (DUREL)
Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being (FACIT-Sp-12) Meaning/Peace subscale

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Narrative MedicineExperimental Treatment1 Intervention
The intervention group will receive a blank composition book with daily writing prompts developed during at least one in-person session with the Narrative Medicine Coordinator to discuss their writing and their writing process.
Group II: Blank composition book with encouragement to writeActive Control1 Intervention
The comparison group will receive a blank composition book with encouragement to write.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Narrative Medicine
2022
N/A
~50

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Narrative Medicine involves reading and discussing literature, followed by guided writing exercises such as poetry, journaling, or creative non-fiction. The mechanisms of action include providing an emotional outlet, fostering self-reflection, and enhancing coping skills. These activities help patients process their experiences, reduce stress, and improve their emotional well-being. This is particularly important for patients in high-stress situations, such as having a child in intensive care, as it aids in making sense of their experiences and supports mental health.
The cerebral circulation and cerebrovascular disease III: Stroke.Overlapping Mechanisms of Stress-Induced Relapse to Opioid Use Disorder and Chronic Pain: Clinical Implications.

Find a Location

Who is running the clinical trial?

Akron Children's HospitalLead Sponsor
49 Previous Clinical Trials
5,008,614 Total Patients Enrolled
Daniel H Grossoehme, DMin, MSPrincipal InvestigatorRebecca D. Considine Research Institute, Akron Children's Hospital

Media Library

Narrative Medicine Clinical Trial Eligibility Overview. Trial Name: NCT05627531 — N/A
Narrative Medicine Research Study Groups: Blank composition book with encouragement to write, Narrative Medicine
Narrative Medicine Clinical Trial 2023: Narrative Medicine Highlights & Side Effects. Trial Name: NCT05627531 — N/A
Narrative Medicine 2023 Treatment Timeline for Medical Study. Trial Name: NCT05627531 — N/A
~13 spots leftby Dec 2025